2017 | 03 | 27

Vironova has filed a US provisional patent for analyzing viral vector content using cryoTEM

Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.

In the pharmaceutical industry, viruses and virus-like particles are extensively used as carriers for gene delivery, so called viral vectors. Assessment of carrier particle content is of prime importance as it is directly linked to the efficacy of the treatment.

Negative stain TEM (nsTEM) is a standard approach for assessing this. Due to variations in staining and preparation the results are unreliable, whereas analysis using cryoTEM yields very consistent and reliable results. Vironova has now filed the patent for the quantitative analysis of viral vector content using cryoTEM.

News and events

Read about the latest news and events at Vironova.

  • All news
  • Inside Vironova
  • Open positions
  • Events and publications
VIEW MORE
VIEW MORE
VIEW MORE
VIEW MORE

Upcoming events 2017

Bioprocess International & Cell and gene therapy bioprocessing
September 25-28 in Boston

  • Exhibition of MiniTEM
  • Technology workshop Tuesday September 26, at 11:50am - 12:20pm
  • Title: Meaningful insights on sub-visible particle morphology, size and purity
  • Speaker: Mathieu Colomb-Delsuc, Senior Scientist

Upcoming webinar October 18

  • Title: MiniTEM Analysis of Viral Vector Particles Provides Insight in Shorter Turnaround Time as Compared to Traditional Assays
  • Speaker: Josefina Nilsson, head of EM services
  • Register here

Vironova on MyNewsDesk

Follow us on MyNewsDesk and get the latest info on investor relations, events and company news.
Click here to get to our MyNewsDesk-page.

Press contact
For press enquiries, please contact
info@vironova.com

IR contact
Mohammed Homman
ceo@vironova.com